Hereditary or Not? Understanding Serrated Polyposis Syndrome
Purpose of review
To present the current understanding of the diagnosis, management, and potential genetic causes of serrated polyposis syndrome.
The clinical criteria for serrated polyposis syndrome was recently updated and now includes individuals with five or more serrated polyps proximal to the rectum that are 5 mm in size or greater and at least two that are 10 mm in size of greater as well as individuals with 20 or more serrated polyps throughout the colon with at least five proximal to the rectum. There is a significant risk for colon cancer in first-degree relatives of individuals with serrated polyposis syndrome. However, less than 3% of serrated polyposis syndrome cases are explained by identifiable germline mutations, with mutations in RNF43 being the only currently validated genetic cause.
Serrated polyposis syndrome is rarely explained by identifiable germline mutations, but there remains an increased risk for colorectal cancer in first-degree relatives. Referral for genetic counseling and testing is recommended for individuals with serrated polyposis syndrome and a personal history of coexisting adenomatous polyposis or with a concerning family history and can be considered for all individuals with serrated polyposis syndrome. Close endoscopic surveillance of those with serrated polyposis syndrome and their first-degree relatives is recommended. Continued efforts at identifying hereditary causes of serrated polyposis are needed.
KeywordsColonic polyps Human Genetics Hyperplastic polyposis syndrome Serrated polyposis syndrome
Compliance with Ethical Standards
Conflict of Interest
PPS has performed collaborative research with Ambry Genetics. RP has performed collaborative research with Ambry Genetics, Myriad Genetics Laboratories, Inc, and InVitae Genetics.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as:• Of importance ••Of major importance
- 1.Snover DC, Ahnen DJ, Burt RW, Odze RD. Serrated polyps of the colon and rectum and serrated polyposis. In: Bozman FT, Carneiro F, Hruban RH, Theise N, editors. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010. p. 160–5.Google Scholar
- 7.Abdeljawad K, Vemulapalli KC, Kahi CJ, Cummings OW, Snover DC, Rex DK. Sessile serrated polyp prevalence determined by a colonoscopist with a high lesion detection rate and an experienced pathologist. Gastrointest Endosc. 2015;81(3):517–24. https://doi.org/10.1016/j.gie.2014.04.064.CrossRefPubMedGoogle Scholar
- 9.Jeevaratnam P, Cottier DS, Browett PJ, Van De Water NS, Pokos V, Jass JR. Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. J Pathol. 1996;179(1):20–5. https://doi.org/10.1002/(SICI)1096-9896(199605)179:1<20::AID-PATH538>3.0.CO;2-C.CrossRefGoogle Scholar
- 14.Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut. 2010;59(8):1094–100. https://doi.org/10.1136/gut.2009.185884.CrossRefGoogle Scholar
- 15.Carballal S, Rodriguez-Alcalde D, Moreira L, Hernandez L, Rodriguez L, Rodriguez-Moranta F, et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut. 2016;65(11):1829–37. https://doi.org/10.1136/gutjnl-2015-309647.CrossRefPubMedGoogle Scholar
- 16.Burt R, Jass JR. Hyperplastic polyposis. In: Hamilton S, Aaltonen LA, editors. Pathology and genetics of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2000. p. 135–6.Google Scholar
- 18.• IJspeert JEG, Bevan R, Senore C, Kaminski MF, Kuipers EJ, Mroz A, et al. Detection rate of serrated polyps and serrated polyposis syndrome in colorectal cancer screening cohorts: a European overview. Gut. 2017;66(7):1225–32. https://doi.org/10.1136/gutjnl-2015-310784 Provided updated prevalence rates for serrated polyposis syndrome and showed that previous reports were likely underestimates.CrossRefPubMedGoogle Scholar
- 22.IJspeert JEG, Rana SA, Atkinson NS, van Herwaarden YJ, Bastiaansen BA, van Leerdam ME, et al. Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut. 2017;66(2):278–84. https://doi.org/10.1136/gutjnl-2015-310630.CrossRefPubMedGoogle Scholar
- 26.•• Rosty C, Brosens LAA, Dekker E, Nagtegaal ID. Serrated polyposis. In: Lokuhetty D, White VA, Watanabe R, Cree IA, editors. WHO classification of tumours: digestive system tumours. Lyon: International Agency for Research on Cancer; 2019. p. 532–4. A major update to the serrated polyposis syndrome diagnostic criteria was introduced in this internationally referenced text.Google Scholar
- 29.Gala MK, Mizukami Y, Le LP, Moriichi K, Austin T, Yamamoto M, et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology. 2014;146(2):520–9. https://doi.org/10.1053/j.gastro.2013.10.045.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Taupin D, Lam W, Rangiah D, McCallum L, Whittle B, Zhang Y, et al. A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred. Hum Genome Var. 2015;2:15013. https://doi.org/10.1038/hgv.2015.13.
- 31.•• Yan HHN, Lai JCW, Ho SL, Leung WK, Law WL, Lee JFY, et al. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut. 2017;66(9):1645–56. https://doi.org/10.1136/gutjnl-2016-311849 Validated link between RNF43 and serrated polyposis syndrome by confirming the second-hit inactivation of the gene in serrated polyps and tumor of affected patients.CrossRefGoogle Scholar
- 32.• Buchanan DD, Clendenning M, Zhuoer L, Stewart JR, Joseland S, Woodall S, et al. Lack of evidence for germline RNF43 mutations in patients with serrated polyposis syndrome from a large multinational study. Gut. 2017;66(6):1170–2. https://doi.org/10.1136/gutjnl-2016-312773 Analyzed RNF43 in the largest cohort of serrated polyposis patients to date and showed that only 2/295 (0.7%) had pathogenic variants.CrossRefGoogle Scholar
- 36.Boparai KS, Dekker E, Van Eeden S, Polak MM, Bartelsman JF, Mathus-Vliegen EM, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology. 2008;135(6):2014–8. https://doi.org/10.1053/j.gastro.2008.09.020.CrossRefPubMedGoogle Scholar
- 37.Guarinos C, Juarez M, Egoavil C, Rodriguez-Soler M, Perez-Carbonell L, Salas R, et al. Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. Clin Cancer Res. 2014;20(5):1158–68. https://doi.org/10.1158/1078-0432.CCR-13-1490.CrossRefPubMedGoogle Scholar
- 38.Clendenning M, Young JP, Walsh MD, Woodall S, Arnold J, Jenkins M, et al. Germline mutations in the polyposis-associated genes BMPR1A, SMAD4, PTEN, MUTYH and GREM1 are not common in individuals with serrated polyposis syndrome. PLoS One. 2013;8(6):e66705. https://doi.org/10.1371/journal.pone.0066705.CrossRefGoogle Scholar
- 39.Petronio M, Pinson S, Walter T, Joly MO, Hervieu V, Forestier J, et al. Type 1 serrated polyposis represents a predominantly female disease with a high prevalence of dysplastic serrated adenomas, without germline mutation in MUTYH, APC, and PTEN genes. United European Gastroenterol J. 2016;4(2):305–13. https://doi.org/10.1177/2050640615594939.CrossRefGoogle Scholar
- 41.Vleugels JLA, Sahin H, Hazewinkel Y, Koens L, van den Berg JG, van Leerdam ME, et al. Endoscopic detection rate of sessile serrated lesions in Lynch syndrome patients is comparable with an age- and gender-matched control population: case-control study with expert pathology review. Gastrointest Endosc. 2018;87(5):1289–96. https://doi.org/10.1016/j.gie.2017.11.034.CrossRefGoogle Scholar
- 48.• Egoavil C, Juarez M, Guarinos C, Rodriguez-Soler M, Hernandez-Illan E, Alenda C, et al. Increased risk of colorectal cancer in patients with multiple serrated polyps and their first-degree relatives. Gastroenterology. 2017;153(1):106–12 e2. Increased risk for colorectal cancer was seen in close relatives of serrated polyposis patients but also in relatives of those with multiple serrated polyps not meeting WHO criteria for serrated polyposis syndrome. This suggests WHO criteria still need optimization to capture individuals and family members at increased risk. https://doi.org/10.1053/j.gastro.2017.04.003.CrossRefGoogle Scholar
- 50.National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1.2019 ed2019.Google Scholar
- 51.Bleijenberg AG, IJspeert JEG, van Herwaarden YJ, Carballal S, Pellise M, Jung G, et al. Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study. Gut. 2019. https://doi.org/10.1136/gutjnl-2018-318134.
- 53.Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. Guideline Development Group ACoMG et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70–87. https://doi.org/10.1038/gim.2014.147.CrossRefPubMedGoogle Scholar